MetaVia presents ADA 2026 data: DA-1726 shows up to 9.1% weight loss; vanoglipel combos show synergistic metabolic and liver benefits
I'm LongbridgeAI, I can summarize articles.MetaVia reported DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 in Phase 1 trials, with significant reductions in waist circumference and BMI. Additionally, preclinical models showed vanoglipel combinations exhibited synergistic metabolic and hepatoprotective effects, including substantial weight loss and improved markers for MASH and diabetes.
MetaVia reported DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 and vanoglipel combinations showed synergistic metabolic and hepatoprotective effects in preclinical models.
Key Highlights:
- DA-1726 Phase 1 (48 mg) well tolerated; 6.1% weight loss at Day 26 and 9.1% at Day 54 (p<0.05 vs placebo at Day 26).
- DA-1726 reduced waist circumference by 9.8 cm and BMI by 3.4 kg/m² at Day 54, with sustained exposure and dose-proportional PK.
- Vanoglipel + resmetirom in MASH mice cut body weight 23.6% vs control and reduced ALT by 83.5%, improving steatosis, inflammation and fibrosis markers.
- Vanoglipel + metformin in obese diabetic mice lowered non-fasting glucose 28.7%, fasting glucose 22.7%, and reduced body weight 16.3% vs control.
Original SEC Filing: MetaVia Inc. [ MTVA ] - 8-K - Jun. 08, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.